Skip to main content
S&P 5007,617.99+0.43%DOW52,125.68+0.06%NASDAQ26,182.76+0.77%BTC$75,733.00-1.00%ETH$2,391.15-1.36%GOLD$4,394.20+1.42%OIL$101.83-3.78%
Smart Investors Daily
ST

NASDAQ · STAA

STAAR Surgical Company

Healthcare · Medical - Instruments & Supplies

$22.45

Up+$0.35 (+1.56%)

Updated Sep 16, 2026, 4:04 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.22B
P/E ratio
-12.83
Dividend yield
0.00%
52-week range
$15.59 – $35.87
Volume
1.08M
Avg. volume
1.06M

Price performance

STAA price history

1M range · 20 trading sessions · Daily adjusted prices

STAA closed at $22.45 after 20 trading sessions, down 8.91% for the selected period.

Last close
$22.45
Period change
-8.91%
Period low
$22.11
Period high
$24.66
Daily close
View OHLC price history
STAA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$23.03$23.03$22.21$22.4451.08M
Sep 14, 2026$22.75$23.155$22.215$23.07798.07K
Sep 11, 2026$23.73$23.78$22.10$22.66838.69K
Sep 10, 2026$23.36$23.741$23.02$23.42680.98K
Sep 9, 2026$23.90$24.265$23.37$23.62827.85K
Sep 8, 2026$23.14$24.355$22.66$24.161.4M
Sep 4, 2026$23.47$24.365$23.40$23.471.97M
Sep 3, 2026$23.15$23.68$22.71$23.575798.35K
Sep 2, 2026$23.41$23.845$23.04$23.11472.78K
Sep 1, 2026$22.59$23.59$22.3583$23.52737.82K
Aug 31, 2026$22.07$22.94$21.77$22.59787.34K
Aug 28, 2026$22.33$22.45$21.89$22.11442.99K
Aug 27, 2026$22.67$22.8211$22.31$22.39565.3K
Aug 26, 2026$22.91$23.165$22.57$22.86427.93K
Aug 25, 2026$23.21$23.46$22.82$23.18523.01K
Aug 24, 2026$23.16$23.56$22.885$23.26562.08K
Aug 21, 2026$23.04$23.46$23.04$23.14698.5K
Aug 20, 2026$24.49$24.75$22.9766$23.07813.28K
Aug 19, 2026$24.77$25.56$24.39$24.661.02M
Aug 18, 2026$24.07$25.025$23.75$24.64928.45K

Latest STAA news

The latest Smart Investors Daily articles mentioning STAA.

Stock researchCompany · Overview

STAA research

Overview

Company profile and research snapshot.

Company profile

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.83
Implied upside
—
Analysts
—
STAA recent ratings
DateFirmRatingTarget
Aug 17, 2026StifelHold—
Aug 13, 2026UBSSell—
Aug 13, 2026WedbushOutperform—
Aug 4, 2026WedbushOutperform—
Jul 28, 2026UBSSell—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 15, 2026

China-Led Rebound and New Leadership Might Change The Case For Investing In STAAR Surgical (STAA)

STAAR Surgical recently reported quarterly net sales of US$93.5 million, an increase of 111% year over year, driven largely by China where revenue more than doubled to US$52.3 million and helped swing the company to US$8.1 million in net income from a loss a year earlier. Alongside this earnings rebound, STAAR strengthened its leadership bench by appointing former CEO David Bailey as Chief Commercial Officer and Ben Park, Ph.D., as Chief Technology Officer, signaling a focus on accelerating...

Yahoo · Sep 15, 2026

STAAR Surgical (STAA) Swings To Profit, Is A 22% Undervalued View Justified?

Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a sharp business turnaround, with net sales rising 111% year over year and net income reaching $8.1 million, helped by China now contributing more than half of revenue. That backdrop sets the stage for two fresh executive appointments at the ophthalmic device producer. These moves could shape how the recent performance is translated into longer term commercial and product decisions. On the market...

Yahoo · Sep 14, 2026

STAAR Surgical (STAA) Swings To Profit On China Rebound

On August 12, STAAR Surgical (NASDAQ:STAA) reported results for the quarter ended July 3 that flipped the script from a year earlier. Net sales jumped 111% year over year to $93.5 million, and the company that lost money in the same quarter of 2025 turned in $8.1 million of net income instead. It is the […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By